Sintilimab-induced autoimmune diabetes: A case report and review of the literature

Figure 1 Mechanism of action of PD-1/PD-L1 immune checkpoint inhibitors. PD-1: Programmed death-1; PD-L1: Programmed death-ligand 1.

Figure 2 Changes of fasting plasma glucose level after initiation of sintilimab.

Figure 3 Course of treatment of patients with diabetes induced by immune checkpoint inhibitors. A: Changes of gastrin-releasing peptide precursor level during each period; B: Contrast-enhanced chest computed tomography during each period. Red arrows indicate the tumors.